Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Sponsor: Dell, Inc.
Listed as NCT02162732, this NA trial focuses on Choroid Plexus Neoplasms and Clear Cell Sarcoma and remains completed. Sponsored by Dell, Inc., it has been updated 19 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
19 versions recorded-
Dec 2025 — Present [monthly]
Completed NA
-
Sep 2025 — Dec 2025 [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
May 2024 — Jul 2024 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
▶ Show 14 earlier versions
-
Oct 2023 — May 2024 [monthly]
Active Not Recruiting NA
-
Feb 2023 — Oct 2023 [monthly]
Active Not Recruiting NA
-
May 2022 — Feb 2023 [monthly]
Active Not Recruiting NA
-
Mar 2022 — May 2022 [monthly]
Active Not Recruiting NA
-
Jan 2021 — Mar 2022 [monthly]
Active Not Recruiting NA
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting NA
-
Aug 2019 — Dec 2020 [monthly]
Active Not Recruiting NA
-
Nov 2018 — Aug 2019 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Aug 2018 — Nov 2018 [monthly]
Recruiting NA
-
Jun 2018 — Aug 2018 [monthly]
Recruiting NA
-
Aug 2017 — Jun 2018 [monthly]
Recruiting NA
-
May 2017 — Aug 2017 [monthly]
Recruiting NA
-
Feb 2017 — May 2017 [monthly]
Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Jul 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Dell, Inc.
- Giselle Sholler
- Translational Genomics Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .